With a baby on the way, Nathan Kirkland was facing a rare, aggressive form of bile duct cancer. Kirkland’s bills piled up as ...

It's a deadly cancer with a complicated name and for too long there've been limited treatment options for sufferers, until ...

Adjuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

Chemoradiation combined with immunotherapy significantly boosts survival in patients with resected extrahepatic ...

NFL Hall of Famer Randy Moss, a bile duct cancer survivor, is returning to ESPN's NFL coverage after a challenging recovery.

The trial is spearheaded by Dr Jonathan Hernandez, the surgical oncology section chief of the National Cancer Institute.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...

The National Cancer Institute and University of Oxford report that oral contraceptive use is not associated with increased ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...